Amgen vs Revolution Medicines (AMGN vs RVMD)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Amgen is the larger company by revenue ($36.8B vs $0) and market value ($196.1B vs $39.6B). Amgen has grown revenue faster over the last 4 fiscal years (+41.5% cumulative vs -100.0%).
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers medicines to treat serious diseases. The company offers products such as Repatha for cardiovascular risk, UPLIZNA for immunoglobulin G4-related disease and myasthenia gravis, and IMDELLTRA for small cell lung cancer. Amgen serves healthcare providers and patients worldwide, with a presence in about 100 countries and sales primarily through pharmaceutical wholesalers and direct-to-patient channels.
About Revolution Medicines
Revolution Medicines, Inc. is a clinical-stage precision oncology company that develops targeted therapies for cancers driven by RAS mutations. The company focuses on small molecule inhibitors called RAS(ON) Inhibitors, designed to target active forms of RAS proteins in various cancers, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. Its pipeline includes multiple oral inhibitors tailored to specific RAS mutations, and it conducts clinical trials to evaluate these therapies in cancer patients.
Head to head (AMGN FY2025 vs RVMD FY2025)
| Metric | AMGNFY2025 | RVMDFY2025 |
|---|---|---|
| Revenue | $36.75B | $0 |
| Revenue growth (YoY) | 10.0% | — |
| Gross margin | 67.2% | — |
| Operating margin | 24.7% | — |
| Net margin | 21.0% | — |
| Net income | $7.71B | $-1.13B |
| Diluted EPS | $14.23 | $-5.95 |
| FCF margin | 22.0% | — |
| ROE | 89.1% | -69.3% |
| Debt / equity | 5.8× | — |
| Market cap | $196.12B | $39.58B |
| P/E (TTM) | 25.3× | — |
Fundamentals are from each company’s SEC filings (AMGN FY2025, RVMD FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| AMGN | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B |
| RVMD | $29.4M | $35.4M | $11.6M | $0 | $0 |
Peer standing
Where each company ranks among the 71 biotech companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | AMGN | RVMD |
|---|---|---|
| ROE | 89.1%93rd percentile of 61 | -69.3%20th percentile of 61 |
| Short interest (days to cover) | 3.93d39th percentile of 71 | 2.99d24th percentile of 71 |
Short interest
| FINRA settlement data | AMGN | RVMD |
|---|---|---|
| Shares sold short | 12.9M | 12.9M |
| Change vs prior settlement | +5.5% | +4.9% |
| Days to cover | 3.93 | 2.99 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | AMGN | RVMD |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 1 ($400,451) | 33 ($24.9M) |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
6 tracked 13F managers hold both Amgen and Revolution Medicines as of their latest quarterly filings: AQR Capital Management, Citadel Advisors, D. E. Shaw, Gotham Asset Management, Millennium Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
AMGN vs BIIBAMGN vs EXELAMGN vs GILDAMGN vs MRNAAMGN vs NBIXAMGN vs TECHAll biotech stocks →All comparisons →
Track AMGN and RVMD
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.